Sedana Medical AB (publ) (SEDANA.ST)
SEK 16.0
(0.38%)
SEK 16.0
(0.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 44.06 Million SEK | -15.97% |
| 2022 | 52.43 Million SEK | -20.71% |
| 2021 | 66.12 Million SEK | 34.94% |
| 2020 | 49 Million SEK | 105.28% |
| 2019 | 23.87 Million SEK | 73.76% |
| 2018 | 13.73 Million SEK | -8.24% |
| 2017 | 14.97 Million SEK | -30.81% |
| 2016 | 21.64 Million SEK | 81.05% |
| 2015 | 11.95 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 64.42 Million SEK | 15.79% |
| 2024 Q1 | 55.63 Million SEK | 26.27% |
| 2024 Q3 | 48.24 Million SEK | -25.11% |
| 2023 Q3 | 47.45 Million SEK | -2.39% |
| 2023 Q4 | 44.06 Million SEK | -7.14% |
| 2023 FY | 44.06 Million SEK | -15.97% |
| 2023 Q1 | 51.61 Million SEK | -1.56% |
| 2023 Q2 | 48.61 Million SEK | -5.81% |
| 2022 FY | 52.43 Million SEK | -20.71% |
| 2022 Q2 | 58.64 Million SEK | -0.87% |
| 2022 Q3 | 53.56 Million SEK | -8.66% |
| 2022 Q4 | 52.43 Million SEK | -2.12% |
| 2022 Q1 | 59.15 Million SEK | -10.53% |
| 2021 Q1 | 44.2 Million SEK | -9.8% |
| 2021 Q2 | 46.5 Million SEK | 5.2% |
| 2021 FY | 66.12 Million SEK | 34.94% |
| 2021 Q4 | 66.12 Million SEK | 35.0% |
| 2021 Q3 | 48.97 Million SEK | 5.32% |
| 2020 Q1 | 24.34 Million SEK | 1.97% |
| 2020 FY | 49 Million SEK | 105.28% |
| 2020 Q4 | 49 Million SEK | 59.67% |
| 2020 Q3 | 30.69 Million SEK | 24.15% |
| 2020 Q2 | 24.71 Million SEK | 1.55% |
| 2019 Q4 | 23.87 Million SEK | 9.26% |
| 2019 FY | 23.87 Million SEK | 73.76% |
| 2019 Q1 | 15.05 Million SEK | 9.6% |
| 2019 Q2 | 17.79 Million SEK | 18.16% |
| 2019 Q3 | 21.84 Million SEK | 22.81% |
| 2018 Q4 | 13.73 Million SEK | -17.14% |
| 2018 FY | 13.73 Million SEK | -8.24% |
| 2018 Q1 | 12.85 Million SEK | -14.14% |
| 2018 Q2 | 15.39 Million SEK | 19.73% |
| 2018 Q3 | 16.57 Million SEK | 7.71% |
| 2017 Q3 | 9.64 Million SEK | -64.29% |
| 2017 Q2 | 27.01 Million SEK | -9.8% |
| 2017 FY | 14.97 Million SEK | -30.81% |
| 2017 Q4 | 14.97 Million SEK | 55.23% |
| 2017 Q1 | 29.94 Million SEK | 38.39% |
| 2016 Q4 | 21.64 Million SEK | 0.0% |
| 2016 FY | 21.64 Million SEK | 81.05% |
| 2015 FY | 11.95 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -300.636% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.352% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.352% |
| Arcoma AB | 33.3 Million SEK | -32.298% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 86.636% |
| BICO Group AB (publ) | 3.26 Billion SEK | 98.65% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 84.258% |
| CellaVision AB (publ) | 212.32 Million SEK | 79.248% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -210.361% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -541.467% |
| C-Rad AB (publ) | 122.4 Million SEK | 64.002% |
| Duearity AB (publ) | 17.53 Million SEK | -151.352% |
| Dignitana AB (publ) | 37.56 Million SEK | -17.289% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -122.535% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.822% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -113.89% |
| Iconovo AB (publ) | 14.55 Million SEK | -202.751% |
| Integrum AB (publ) | 22.07 Million SEK | -99.621% |
| Luxbright AB (publ) | 7 Million SEK | -529.446% |
| Mentice AB (publ) | 163.55 Million SEK | 73.06% |
| OssDsign AB (publ) | 105.25 Million SEK | 58.139% |
| Paxman AB (publ) | 44.5 Million SEK | 1.004% |
| Promimic AB (publ) | 16.15 Million SEK | -172.728% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 29.125% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -107.078% |
| ScandiDos AB (publ) | 37.18 Million SEK | -18.491% |
| Sectra AB (publ) | 1.64 Billion SEK | 97.315% |
| Senzime AB (publ) | 58.06 Million SEK | 24.116% |
| SpectraCure AB (publ) | 14.97 Million SEK | -194.237% |
| Stille AB | 172.64 Million SEK | 74.478% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 98.799% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 82.415% |